sarilumab (Kevzara)
Jump to navigation
Jump to search
Indications
- rheumatoid arthritis (FDA-approved 5/17)
- active polyarticular juvenile idiopathic arthritis (FDA-approved 6/24)
- relapsing polymyalgia rheumatica[4]
* also see IL-6 inhibitors for COVID-19
Dosage
- 200 mg every 2 weeks
Adverse effects
- drug adverse effects of immunosuppressive agents
- drug adverse effects of biologic immunosuppressive agents
- drug adverse effects of pharmaceutical monoclonal antibodies
Mechanism of action
- human monoclonal antibody, inhibits IL-6 receptor
Management
- whenever possible bring patients up to date on vaccinations prior to initiating biologic immunosuppressive agent[3]
Notes
- superior to adalimumab (Humira) monotherapy
More general terms
Additional terms
- interleukin-6 receptor
- interleukin-6; IL-6; B-cell stimulatory factor 2; BSF-2; CTL differentiation factor; CDF; hybridoma growth factor; interferon beta-2; IFN-beta-2 (IL6, IFNB2)
References
- ↑ Burmester GR, Lin Y, Patel R et al Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. Nov 17, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27856432 Free full text <Internet> http://ard.bmj.com/content/early/2016/11/16/annrheumdis-2016-210310.abstract
- ↑ Frellick M FDA Approves Sarilumab for Adults With Rheumatoid Arthritis Medscape - May 23, 2017. http://www.medscape.com/viewarticle/880473
- ↑ 3.0 3.1 3.2 Medical Knowledge Self Assessment Program (MKSAP) 19 American College of Physicians, Philadelphia 2022
- ↑ 4.0 4.1 Spiera RF et al. Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper. N Engl J Med 2023 Oct 5; 389:1263. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37792612 https://www.nejm.org/doi/10.1056/NEJMoa2303452